Jon O. Curwen

AstraZeneca, Alderley Park
Macclesfield, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists.

Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists.

Journal: Journal of medicinal chemistry

Published: January 15, 2019

Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer.

Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer.

Journal: Molecular cancer therapeutics

Published: June 11, 2017

Design, analysis and reporting of tumor models.

Design, analysis and reporting of tumor models.

Journal: Lab animal

Published: April 20, 2017

Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R).

Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R).

Journal: Journal of medicinal chemistry

Published: April 15, 2016

Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.

Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.

Journal: Journal of medicinal chemistry

Published: September 26, 2015

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.

Journal: Cancer research

Published: August 28, 2015

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.

Journal: Molecular cancer therapeutics

Published: May 06, 2015

Prevention of fostamatinib-induced blood pressure elevation by antihypertensive agents.

Prevention of fostamatinib-induced blood pressure elevation by antihypertensive agents.

Journal: Pharmacology research & perspectives

Published: April 09, 2015

In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib.

In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib.

Journal: Pharmacology research & perspectives

Published: April 09, 2015

The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation.

The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation.

Journal: British journal of pharmacology

Published: July 23, 2013

Showing 1-10 of 10

Last Updated: 09/26/2026